BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20162514)

  • 21. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
    Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
    Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
    Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical significance of serum neuron-specific enolase in non-small cell lung cancer].
    Kimura H; Yamaguchi T; Nishino K; Nakagawa M; Yokota S; Nishikawa H; Ito M; Ogura T
    Nihon Kokyuki Gakkai Zasshi; 1998 Feb; 36(2):128-32. PubMed ID: 9617138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
    Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
    Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
    van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.
    Tiseo M; Ardizzoni A; Cafferata MA; Loprevite M; Chiaramondia M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Anticancer Res; 2008; 28(1B):507-13. PubMed ID: 18383893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
    Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Level of carcinoembryonic antigen, neuron-specific enolase and ferritin in serum of small cell lung cancer patients: correlation with performance status, disease extent and prognosis].
    Szturmowicz M; Rogińska E; Roszkowski K; Kwiek S; Filipecki S; Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 1993; 61(9-10):467-73. PubMed ID: 8111322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
    Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
    Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.